LLY Latest Press Releases

-- October 6, 2026 --

Wound Care Stocks Are Posting Double-Digit Growth. Here's Why. Globe Newswire 9:06 AM

-- October 5, 2026 --

Lilly to present new data across its dermatology portfolio with 21 presentations at Fall Clinical 2026, in pursuit of advancing care for chronic skin conditions PRNewswire 7:51 AM

-- October 2, 2026 --

Lilly's Jaypirca (pirtobrutinib), the first-and-only approved non-covalent BTK inhibitor, receives expanded indication from U.S. FDA for certain patients with previously untreated CLL/SLL PRNewswire 3:06 PM

-- October 1, 2026 --

Lilly's oral GLP-1, Foundayo (orforglipron), was associated with significant reductions in predicted long-term risk of type 2 diabetes and cardiovascular disease PRNewswire 7:00 AM

-- September 30, 2026 --

Lilly's oral GLP-1, Foundayo (orforglipron), demonstrated cardiovascular safety alongside sustained A1C reduction and weight loss in its largest and longest type 2 diabetes study PRNewswire 6:01 PM

3 Biotech Stocks Throwing Their Weight Around, and Another that Wants to Help You Lose Yours Globe Newswire 10:22 AM

Lilly's EloraTZP (combination of eloralintide and tirzepatide) delivered greater weight loss and A1C reduction vs. tirzepatide 15 mg in adults with obesity and type 2 diabetes PRNewswire 10:15 AM

New Phase 3b data show Lilly's EBGLYSS (lebrikizumab-lbkz) delivered significant and rapid improvements in skin clearance, itch, pain, and patient satisfaction in people with moderate-to-severe hand and foot atopic dermatitis PRNewswire 8:03 AM

-- September 29, 2026 --

Lilly's triple agonist, retatrutide, delivered substantial weight loss and A1C reduction, underscoring its potential promise for people with obesity and type 2 diabetes PRNewswire 6:00 PM

Lilly's Zepbound (tirzepatide 10 mg and 15 mg) was associated with more weight loss than Wegovy HD (semaglutide injection 7.2 mg) in a new indirect treatment comparison PRNewswire 7:01 AM

Lilly's Foundayo (orforglipron) 17.2 mg showed greater weight loss and A1C reduction than oral semaglutide 25 mg among adults with type 2 diabetes in a new indirect treatment comparison PRNewswire 3:01 AM

-- September 28, 2026 --

Lilly launches the Lilly Change the Course Commitment, aiming to address treatment gaps in diabetes and obesity in LMICs PRNewswire 6:45 AM

-- September 25, 2026 --

FDA approves Lilly's Olumiant (baricitinib) for pediatric patients 12 years of age and older with severe alopecia areata PRNewswire 5:12 PM

-- September 24, 2026 --

U.S. Food and Drug Administration (FDA) approves Lilly's Onswik (insulin efsitora alfa-gobe), a once-weekly basal insulin injection treatment for adults living with type 2 diabetes PRNewswire 6:45 AM

-- September 21, 2026 --

Lilly breaks ground in Houston, one of ten U.S. manufacturing sites announced since 2020 PRNewswire 5:40 PM

-- September 18, 2026 --

U.S. FDA approves Inluriyo (imlunestrant) in combination with Verzenio (abemaciclib) for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer PRNewswire 1:55 PM

-- September 15, 2026 --

Lilly to present new data on Foundayo, retatrutide, and eloraTZP at EASD 2026, as it strives to change the course of cardiometabolic health PRNewswire 6:46 AM

-- September 11, 2026 --

Lilly completes acquisition of AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions PRNewswire 9:03 AM

-- September 1, 2026 --

Lilly to participate in Morgan Stanley 24th Annual Global Healthcare Conference PRNewswire 10:01 AM

-- August 31, 2026 --

New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy at one year in adults with psoriatic disease and obesity PRNewswire 7:01 AM

Lilly to acquire Merida Biosciences to advance treatments for serious autoimmune and allergic diseases PRNewswire 6:45 AM

-- August 28, 2026 --

AtaiBeckley Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of AtaiBeckley Inc. - ATAI PRNewswire 2:28 PM

FDA approves Lilly's Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes PRNewswire 7:01 AM

-- August 26, 2026 --

Zepbound linked to lower healthcare costs in adults over age 55 with obesity according to a real-world study PRNewswire 6:45 AM

-- August 19, 2026 --

Most AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does. Globe Newswire 8:56 AM

-- August 18, 2026 --

A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It. Globe Newswire 12:57 PM

-- August 17, 2026 --

AtaiBeckley Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of AtaiBeckley Inc. - ATAI Business Wire 1:05 PM

-- August 12, 2026 --

The GLP-1 Boom Created a Tissue Gap Fillers Were Not Built For Globe Newswire 9:15 AM

Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market PRNewswire 5:31 AM

-- August 5, 2026 --

Lilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progress PRNewswire 6:45 AM

-- August 3, 2026 --

Lilly's olomorasib receives U.S. FDA's Breakthrough Therapy designation for the treatment of previously treated KRAS G12C-mutant advanced pancreatic cancer PRNewswire 7:45 AM

-- July 23, 2026 --

Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C PRNewswire 6:45 AM

-- July 22, 2026 --

Lilly confirms date and conference call for second-quarter 2026 financial results announcement PRNewswire 10:00 AM

-- July 17, 2026 --

AtaiBeckley Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of AtaiBeckley Inc. - ATAI Business Wire 2:57 PM

-- July 16, 2026 --

Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions PRNewswire 6:45 AM

-- July 15, 2026 --

Three Biotechs Deliver Catalysts to Watch Globe Newswire 10:42 AM

-- July 9, 2026 --

/C O R R E C T I O N -- Eli Lilly and Company/ PRNewswire 1:17 PM

Lilly to present Alzheimer's disease diagnostic and therapeutic research at AAIC 2026, including new data on P-tau217 blood tests and amyloid-targeting treatment PRNewswire 7:31 AM

-- July 7, 2026 --

A $190 Billion Weight-Loss Boom Exposed a Tissue-Restoration Gap, and One Nasdaq Company Is Moving to Fill It PRNewswire 9:45 AM

-- July 1, 2026 --

A Nasdaq-Listed Regenerative Tissue Company Just Opened a Lab: The Next Step in Scaling a Platform Built for a NEW Aesthetics Opportunity Globe Newswire 9:05 AM

-- June 30, 2026 --

Innovent Biologics and Lilly Enter into Commercialization Agreement for Verzenios (abemaciclib) in Mainland China PRNewswire 12:01 AM

-- June 26, 2026 --

Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy PRNewswire 7:17 AM

-- June 25, 2026 --

What Medicare Part D patients need to know about accessing Foundayo (orforglipron) and Zepbound (tirzepatide) for weight management PRNewswire 6:45 AM

-- June 24, 2026 --

Lilly completes acquisition of Centessa Pharmaceuticals to advance treatments for sleep-wake disorders PRNewswire 8:45 AM

-- June 22, 2026 --

Lilly declares third-quarter 2026 dividend PRNewswire 11:00 AM

International Regulatory Pathways Have Supported Drug Development Across Biotech and Pharma Globe Newswire 9:05 AM

-- June 14, 2026 --

Lilly's Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLL PRNewswire 3:15 AM

-- June 13, 2026 --

Lilly to present initial clinical data for first-in-class type II JAK2 inhibitor in patients with previously treated myelofibrosis at the 2026 EHA Annual Meeting PRNewswire 11:15 AM

-- June 10, 2026 --

Zepbound (tirzepatide) and Shaquille O'Neal launch national campaign after NBA legend learns the obstructive sleep apnea he has lived with for years is treatable PRNewswire 9:30 AM

-- June 9, 2026 --

FDA approves Lilly's EBGLYSS (lebrikizumab-lbkz) for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitis PRNewswire 6:19 PM

Convatec and Lilly Foundation Commit $5m to Partners In Health to Improve Care for Non-communicable Disease and Chronic Conditions Business Wire 4:00 AM

-- June 8, 2026 --

Lilly's oral GLP-1 Foundayo (orforglipron) delivered superior A1C control and weight loss in three pivotal type 2 diabetes trials PRNewswire 2:30 PM

-- June 7, 2026 --

Lilly's Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage of menopause PRNewswire 11:00 AM

-- June 6, 2026 --

Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and its complications PRNewswire 2:30 PM

-- June 2, 2026 --

Lilly to spotlight growing hematology portfolio at 2026 European Hematology Association (EHA) Annual Meeting PRNewswire 9:30 AM

-- June 1, 2026 --

Lilly's Cancer Bombshell Sparks Hunt for the Next Oncology Stock Set to Explode Globe Newswire 9:05 AM

-- May 31, 2026 --

Lilly's Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with early-stage RET fusion-positive lung cancer PRNewswire 8:01 AM

-- May 28, 2026 --

Lilly to present new data on Foundayo, Mounjaro and retatrutide at the American Diabetes Association's 86th Scientific Sessions, building toward a new era of choice in diabetes and obesity care PRNewswire 1:00 PM

Foundayo and Zepbound now covered for millions of Americans PRNewswire 6:45 AM

-- May 27, 2026 --

Lilly to participate in Goldman Sachs 47th Annual Global Healthcare Conference PRNewswire 11:15 AM

-- May 26, 2026 --

Lilly announces three acquisitions to build infectious disease portfolio PRNewswire 6:45 AM

-- May 25, 2026 --

A single dose of Lilly's PCSK9 base editor, VERVE-102, reduced PCSK9 by up to 88% and LDL-C by up to 62%, with durable effects supporting its potential as a one-time treatment for hypercholesterolemia PRNewswire 8:45 AM

-- May 21, 2026 --

Lilly to showcase oncology portfolio across tumor types and treatment modalities at the 2026 American Society of Clinical Oncology Annual Meeting PRNewswire 5:00 PM

Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets Globe Newswire 9:00 AM

Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial PRNewswire 6:45 AM

-- May 18, 2026 --

Lilly to participate in Bernstein's 42nd Annual Strategic Decisions Conference PRNewswire 10:00 AM

-- May 16, 2026 --

Lilly, Caitlin Clark Foundation, and Musco Lighting open three community sports courts in Indianapolis, expanding year-round access for youth PRNewswire 11:00 AM

-- May 14, 2026 --

Lilly and UNICEF collaborate to give millions of children a healthier start PRNewswire 7:00 AM

-- May 12, 2026 --

Lilly's Foundayo and lower-dose Zepbound helped people maintain weight loss after switching from higher doses of injectable incretin therapy in two late-phase trials PRNewswire 6:01 PM

In honor of its 150th anniversary, Eli Lilly and Company commits to support community organizations aiming to provide 500,000 meals and cold storage for 150 food pantries PRNewswire 12:00 PM

Peptide Wellness Market Could Near $300 Billion as Consumer Demand Accelerates Globe Newswire 9:00 AM

-- May 11, 2026 --

Centessa Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Centessa Pharmaceuticals plc - CNTA Business Wire 12:43 PM

The Next Generation of the GLP-1 Revolution Is Already Underway Globe Newswire 8:30 AM

-- May 7, 2026 --

Biotech's Next Wave May Already be in Motion Globe Newswire 8:45 AM